FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Mga view· 09/21/23
OncLive® On Air
OncLive® On Air
0 Mga subscriber
0
Sa

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Magpakita ng higit pa

 0 Mga komento sort   Pagbukud-bukurin Ayon


Susunod